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a significantly better side-effect profile. METHOD: A
longitudinal study was conducted using drug claims from
PCS Health Systems. The study cohort consists of 4602
“naïve tolterodine users”, 7291 “naïve oxybutynin us-
ers” and 2127 “naive flavoxate users.” Survival analysis
was used to estimate the “persistence rate”—defined as
the proportion of patients who are still on a drug treat-
ment during or after a defined period of continuous treat-
ment for the drug. A Cox-regression model was used to
assess the net effect of using tolterodine or oxybutynin on
the persistence of drug therapy controlling for differences
in the patients’ demographics, comorbid conditions, and
other factors. RESULTS: The persistence on tolterodine
was 30% higher than that on oxybutynin on continuous
treatment periods of 31–60 days, and 90% higher for
301–360 days of therapy. The persistence on tolterodine
was 430% higher than that on flavoxate for treatment
periods of 30–60 days and 340% higher for 301–360
days of therapy. The average length of continuous treat-
ment for naive tolterodine users was the longest of the
three drugs: 143(3.9) days compared to 91(2.6) days for
oxybutynin and 41(4.6) days for flavoxate. The adjusted
odds-ratio of terminating drug treatment for tolterodine
vs. oxybutynin users was 0.66 (p  0.001). CONCLU-
SIONS: Patients using tolterodine were significantly more
likely to continue their treatment than those choosing
other OAB drugs. The better persistence for tolterodine
users should result in longer symptom relief for patients,
particularly for those who are in need of long-term treat-
ment but are distressed by side effects.
PUR4
ANALYSIS OF COMORBIDITY IN OVERACTIVE 
BLADDER AND URINARY INCONTINENCE IN A 
MANAGED CARE ORGANIZATION
Juzba M, White TJ, Chang EY
Prescription Solutions, Costa Mesa, CA, USA
OBJECTIVE: The primary objectives of this study are to
examine the costs of overactive bladder and urinary in-
continence (OAB/UI) and evaluate for the presence of de-
pression and falls and fractures as comorbid conditions
from a managed care perspective. METHOD: Retrospec-
tive computerized claims records from a managed care
organization were analyzed. Patients were included if
they had an ICD-9 code consistent with OAB or UI, were
under treatment and were continuously eligible between
1/1/99 and 12/31/99 (N  445). Randomly sampled con-
trol patients from the general membership were matched
on age and gender with the OAB/UI group at a ratio of
5:1 (N  2,220). Diagnoses of depression and of falls,
fractures and contusions were collected and a Charlson
comorbidity index was developed for all study patients.
Depression-related costs and falls & fracture-related
costs included those directly related to treatment. RE-
SULTS: Seventeen (0.77%) of the control patients had a
diagnosis of depression compared to 2.02% of the OAB/UI
patients (P  0.0001). Of the OAB/UI patients, 13.93%
were diagnosed with a fall or fracture compared to 8.11%
of the control patients (P  0.0001). The mean Charlson
score of the OAB/UI group was 0.51 (SD 1.10) compared
to 0.37 (SD 1.00) for the control group (P  0.01). The
mean cost of treating depression was $33 (SD $605) for
the control group and $42 (SD $138) for the OAB/UI
group (P  0.0001). The average cost of treating falls &
fractures was $154 (SD $1,922) for the control group
and $434 (SD $4,946) for the OAB/UI group (P  0.0001).
CONCLUSION: Compared to the general population, pa-
tients with a diagnosis of OAB/UI are significantly more
likely to experience a fall or fracture or experience de-
pression. They also tend to have a significantly higher
burden of comorbidity. The average cost of fall & frac-
ture treatment and treatment of depression is signifi-
cantly higher among OAB/UI patients.
PUR5
THE IMPACT OF PHARMACOTHERAPY ON 
OVERACTIVE BLADDER SYMPTOM 
IMPROVEMENT AND RESOURCE UTILIZATION
Pashos CL1, Grossman M1, Bull S2
1Abt Associates Clinical Trials, Cambridge, MA, USA; 2Alza 
Corporation, Mountain View, CA, USA
OBJECTIVES: To examine the effects of drug treatment
on overactive bladder (OAB) symptom improvement and
resource utilization. METHODS: We conducted an ob-
servational study of 217 OAB patients enrolled by 31
physicians nationwide. One hundred twenty-two patients
have been tracked through 3 months to determine symp-
tom improvement, change(s) in treatment, and resource
utilization. The impact of medication on OAB symptom
improvement was modeled using stepwise logistic regres-
sion adjusting for patient age, sex, symptom duration,
symptom severity, incontinence, frequency of leakage ac-
cidents, and frequency of urinations. RESULTS: Partici-
pants averaged 60.7 years old (S.D.  15.7), 85.2% were
female, and the mean duration of OAB symptoms was
8.1 years. On average, patients experienced 11.0 uri-
nations per day (S.D.  4.7) and 2.2 accidents per day
(S.D.  3.4). Treatment with medication increased the
odds of symptom improvement by four-fold (odds ratio
(O.R.)  4.3, 95% confidence interval (CI) 1.8–9.9). Pa-
tients with incontinence were significantly more likely to
report improvement in symptoms compared with pa-
tients with urinary frequency alone (O.R.  3.2, 95%CI
1.2–8.4). Nineteen of 72 (26%) patients not started on
medication at baseline began medication within the first
3 months, consuming an average of 1.16 office visits per
patient. In contrast, 11 of 50 patients (22%) who were
started on medication at baseline discontinued within the
first 3 months, consuming an average of 0.64 office visits
per patient. Patients staying on medication (39/50, 78%)
consumed on average the fewest office visits per patient
(0.15), while patients who managed symptoms without
medication (53/72, 73%) consumed an average of 0.26
office visits. CONCLUSIONS: Pharmacotherapy signifi-
